Bronchodilator Drugs - Bahrain | Statista Market Forecast

The Bronchodilator Drugs market in Bahrain is projected to reach a revenue of US$4.43m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 3.71%, resulting in a market volume of US$5.32m by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$17.34bn in 2024.
In Bahrain, the demand for bronchodilator drugs has been steadily increasing due to the high prevalence of respiratory diseases in the country.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are a crucial part of the treatment for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In Bahrain, the market for bronchodilator drugs has been showing some interesting trends and developments.

Customer preferences: Bronchodilator drugs are primarily used to relieve symptoms such as coughing, wheezing, and shortness of breath in patients with respiratory diseases. In Bahrain, there is a growing preference for combination bronchodilator drugs that contain both short-acting and long-acting medications. This is because these drugs provide immediate relief as well as long-term control of symptoms.

Trends in the market: One of the major trends in the bronchodilator drugs market in Bahrain is the increasing demand for inhalers. Inhalers are preferred over other forms of medication such as tablets or syrups because they deliver the medication directly to the lungs, resulting in faster and more effective relief of symptoms. Another trend in the market is the growing popularity of generic bronchodilator drugs. These drugs are cheaper than their brand-name counterparts and are equally effective.

Local special circumstances: Bahrain has a high prevalence of respiratory diseases such as asthma and COPD. This is partly due to the country's hot and humid climate, which can trigger respiratory symptoms in susceptible individuals. Additionally, Bahrain has a high prevalence of smoking, which is a major risk factor for respiratory diseases. These local circumstances have contributed to the growth of the bronchodilator drugs market in Bahrain.

Underlying macroeconomic factors: Bahrain has a well-developed healthcare system that provides universal coverage to its citizens. This has led to increased access to healthcare services, including medications such as bronchodilator drugs. Additionally, Bahrain has a growing population, which has led to an increase in the number of individuals with respiratory diseases. These underlying macroeconomic factors have contributed to the growth of the bronchodilator drugs market in Bahrain.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.